| Serial Number | 79149533 |
| Word Mark | LUMITIN |
| Filing Date | Friday, March 28, 2014 |
| Status | 404 - IR CANCELLED - US REGISTRATION CANCELLED |
| Status Date | Friday, March 29, 2024 |
| Registration Number | 4741346 |
| Registration Date | Tuesday, May 26, 2015 |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, March 10, 2015 |
| Description of Mark | The mark consists of the words "LUMITIN". |
| Goods and Services | Medicines for humans used for the treatment of choroidal neovascularization induced by high myopia, macular edema induced by retinal vein occlusion, diabetic macular edema, wet age-related macular degeneration accompanied by very low vision acuity, the inhibition of neovascularization, back-of-the-eye neovascularization, aged-relatedmacular degeneration, retinal vein occlusion, neoplastic disease and cancer, angiogenesis disease; Pharmaceutical preparations for the treatment of diabetes, cardiovascular disease and disorder, neoplastic disease and disorder, cancer, disease and disorder of immune system, angiogenesis disease and disorder, ophthalmic diseases and disorder, mental disease and disorder, aged-related macular degeneration; Injectable preparations for medical use, namely, for the treatment of oculopathy, choroidal neovascularization induced by high myopia, macular edema induced by retinal vein occlusion, diabetic macular edema, wet age-related macular degeneration accompanied by very low vision acuity, the inhibition of neovascularization, back-of-the-eye neovascularization, aged-related macular degeneration, retinal vein occlusion, neoplastic disease, angiogenesis disease and cancer; Aqueous formula, namely, water-based pharmaceutical preparations for the treatment of cardiovascular disease and disorder, neoplastic disease and disorder, disease and disorder of immune system, ophthalmic diseases and disorder, inflammation; Biochemical drugs and preparations for medical use, namely, for the prevention, treatment and alleviation of angiogenesis disease, oculopathy, neoplastic disease, cancer, all of the foregoing being available by prescription only |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Translation of Words in Mark | The wording "LUMITIN" has no meaning in a foreign language. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | F - NOT AVAILABLE |
| Class Status Date | Friday, December 10, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Chengdu Kanghong Pharmaceuticals GroupCo., Ltd. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | CN |
| Party Name | Chengdu Kanghong Pharmaceuticals GroupCo., Ltd. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | CN |
| Party Name | Chengdu Kanghong Pharmaceuticals GroupCo., Ltd. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | CN |
| Event Date | Event Description |
| Friday, August 1, 2014 | REFUSAL PROCESSED BY MPU |
| Thursday, July 24, 2014 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Tuesday, July 29, 2014 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, July 29, 2014 | ASSIGNED TO EXAMINER |
| Thursday, July 31, 2014 | NON-FINAL ACTION WRITTEN |
| Friday, August 1, 2014 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, February 18, 2015 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, March 10, 2015 | PUBLISHED FOR OPPOSITION |
| Friday, August 1, 2014 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Saturday, August 2, 2014 | APPLICATION FILING RECEIPT MAILED |
| Friday, August 22, 2014 | REFUSAL PROCESSED BY IB |
| Tuesday, January 6, 2015 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, January 8, 2015 | ASSIGNED TO LIE |
| Thursday, January 8, 2015 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, January 8, 2015 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, January 29, 2015 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Saturday, January 31, 2015 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Wednesday, August 26, 2015 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Friday, December 10, 2021 | CANCELLED SECTION 71 |
| Tuesday, March 10, 2015 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 26, 2015 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, September 23, 2015 | FINAL DISPOSITION PROCESSED |
| Wednesday, September 23, 2015 | FINAL DISPOSITION NOTICE SENT TO IB |
| Friday, October 9, 2015 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Tuesday, May 26, 2020 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Saturday, June 5, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Thursday, September 22, 2022 | GENERIC MADRID TRANSACTION SENT TO IB |
| Friday, October 18, 2024 | DEATH OF INTERNATIONAL REGISTRATION |
| Friday, October 18, 2024 | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED |
| Monday, October 31, 2022 | TOTAL INVALIDATION PROCESSED BY THE IB |
| Wednesday, August 10, 2022 | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED |
| Thursday, September 22, 2022 | GENERIC MADRID TRANSACTION CREATED |